Immune checkpoint blockade: releasing the breaks or a protective barrier to COVID-19 severe acute respiratory syndrome?
Oliver Pickles, Lennard Y. W. Lee, Thomas Starkey, Luke Freeman-Mills, Anna Olsson‐Brown, Vinton W.T. Cheng, D.J. Hughes, Alvin Lee, Karin Purshouse, Gary Middleton
Abstract
The rapid emergence of COVID-19 has sent shockwaves through healthcare systems globally, with cancer patients at increased risk. The interplay of the virus and host immune system has been implicated in the development of ARDS. Immunotherapy agents have the potential to adversely potentiate this phenomenon, requiring careful real-world observation.
Topics & Concepts
ARDSImmunotherapyImmune systemBlockadeMedicineCoronavirus disease 2019 (COVID-19)ImmunologyImmune checkpointRespiratory systemSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)DiseaseLungPathologyInternal medicineInfectious disease (medical specialty)ReceptorCOVID-19 Clinical Research StudiesCOVID-19 and healthcare impactsCancer Immunotherapy and Biomarkers